Relapses & Outcomes: Why Consistency Matters for Patient Recovery

Schizophrenia is a severe mental illness that significantly impacts cognition, emotions, and social interactions, with affected individuals facing a reduced life expectancy of 15 to 20 years. In this module, Dr. Christoph U. Correll, a leading expert in psychiatry, explores the limitations of current dopamine-blocking therapies and discusses emerging strategies to improve schizophrenia treatment. STATEMENT OF NEED Schizophrenia is a debilitating mental illness characterized by psychotic symptoms and disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Individuals with schizophrenia have an estimated life expectancy 15 to 20 years less than that of the general population (National Institute of Mental Health, 2024; Kantrowitz et al, 2023). The shortcomings of available dopamine blocking agents to treat schizophrenia and ongoing efforts to optimize therapy will be discussed in Module 1 of this activity, led by Dr. Christoph U. Correll, Professor of Psychiatry and Molecular Medicine at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, and Professor and Chair of the Department of Child and Adolescent Psychiatry at Charité – University Medicine in Berlin, Germany. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Christoph U. Correll, MD, discloses that he has served on an advisory board or panel for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol Meyers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Life Science, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, and Viatris; that he has served as a consultant for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol Meyers Squibb, Cerevel, Compass, Denovo, Eli Lilly, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Life Science; Lundbeck, MedInCell, Medlink, Merck, Mindpax, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, and Viatris; that he has received grants/research support from Boehringer-Ingelheim, Janssen, and Takeda; and that he is a stock/shareholder with Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. i3 Health has mitigated all relevant financial relationships. #Schizophrenia #MentalHealth #Psychiatry #Neuroscience #Psychopharmacology #Dopamine #BrainHealth #Psychosis #MedicalEducation #mentalhealthawareness